المملكة: Urgent: “Food and Drug” records the first treatment for Alzheimer’s disease in the Kingdom using antibody technology
The Food and Drug General Authority announced the registration of a “celibi” product (Likanimab) as the first treatment to be officially adopted for Alzheimer’s disease in the Kingdom of Saudi Arabia, to treat patients with a simple perception or a light stage of dementia, provided that they do not carry any copy or carry only one copy of one of the forms of the core of the lipogy protein (APOE4), which is the gene associated with increasing the risk of the disease. />
A “Kambi” preparation is an innovative, innovative, vital treatment that is based on the category of innovative and manufactured antibodies with monochrome antibodies, and is considered the first vibrant treatment that is officially adopted for Alzheimer’s disease in the Kingdom. This treatment targets the accumulated beta amyloid protein in the brain, which is the protein that is plaques that leads to the deterioration of cognitive abilities in Alzheimer’s patients. By working to reduce the accumulation of these plaques, the product contributes to slowing the progress of the disease and improving the quality of patients ’life. The product is given by venous leakage once every two weeks. It showed that the clinical studies conducted on the product showed positive results in slowing the deterioration of the pathological condition compared to the imaginary therapy, based on the clinical standards used globally in assessing the effectiveness of Alzheimer’s disease. Associated with the intravenous leakage process, in addition to changes in MRI associated with jumped protein, known as the term (ARIA), a term indicating abnormal brain changes that can be monitored through magnetic resonance imaging, and these changes include cases such as stroke or precise bleeding. The minute and periodic for patients during the treatment period in the preparation, especially with regard to monitoring and evaluating possible side effects, and stressed the need to conduct an accurate assessment of the patient’s genetic condition before the start of treatment, with the aim of reducing the possibility of the occurrence of side effects associated with the drug. The “food and medicine” also stipulated that the manufacturer adhere to follow -up of post -marketing data, and to provide updated periodic reports on the effectiveness and safety of the preparation, in addition to implementing a comprehensive risk management plan, ensuring the optimal and safe use of this new biological treatment. And quality for patients in the Kingdom of Saudi Arabia, especially those based on biotechnology applications, which are witnessing an accelerated scientific development at the global level. This achievement also reflects the authority’s commitment to achieving the targets of the health sector transformation program, one of the executive programs for the Kingdom’s 2030 vision, which aims to improve the quality and efficiency of health services provided to citizens and residents, and to facilitate their obtaining the latest international remedies.
- For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter
